Latest Pharma Insights
FDA Issues Early Alert On Medline Syringes
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026
Biocon Secures Health Canada Approval For Two Denosumab Biosimilars
Following two more approvals from Health Canada, biosimilars Bosaya and Vevzuo are ready to compete for their market share of denosumab success.
Generics Bulletin - April 24, 2026
Following two more approvals from Health Canada, biosimilars Bosaya and Vevzuo are ready to compete for their market share of denosumab success.
Generics Bulletin - April 24, 2026
EU Unlocks New Funding For Health AI Projects
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026
Europe Widens Competition Path For Generic Peptides
Europe’s top court has ruled that synthetic medicines may use the EU generic pathway even when the reference product is a biologic, provided Article 10 criteria are met, in a decision with potentially significant implications for peptide competition.
Generics Bulletin - April 24, 2026
Europe’s top court has ruled that synthetic medicines may use the EU generic pathway even when the reference product is a biologic, provided Article 10 criteria are met, in a decision with potentially significant implications for peptide competition.
Generics Bulletin - April 24, 2026
EU Nod Arrives For Viatris’s Ibrance Rival
As Viatris received a positive opinion from the EMA’s CHMP for its palbociclib generic, Intas also racked up an endorsement for the region's latest biosimilar rival to Lucentis.
Generics Bulletin - April 24, 2026
As Viatris received a positive opinion from the EMA’s CHMP for its palbociclib generic, Intas also racked up an endorsement for the region's latest biosimilar rival to Lucentis.
Generics Bulletin - April 24, 2026
Interparfums Navigating ‘More Selective’ Consumers As Q1 Sales Rise
Fragrances specialist Interparfums highlighted the headwinds facing its business, and the wider industry, as it reported a rise in first-quarter sales.
HBW Insight - April 24, 2026
Fragrances specialist Interparfums highlighted the headwinds facing its business, and the wider industry, as it reported a rise in first-quarter sales.
HBW Insight - April 24, 2026
Pipeline Watch: Twelve Approvals And Nine Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 24, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 24, 2026
Hansa’s Europe Miss For Lead Drug Raises US Launch Stakes
Hansa’s launch preparations are underway ahead of an expected US FDA decision on imlifidase, its desensitization therapy for kidney transplant patients, later this year.
Scrip - April 24, 2026
Hansa’s launch preparations are underway ahead of an expected US FDA decision on imlifidase, its desensitization therapy for kidney transplant patients, later this year.
Scrip - April 24, 2026
Towa Builds Further Backup Network For Drug Shortages
Towa has agreed a manufacturing pact with Sanwa Kagaku Kenkyusho to add backup production capacity, outsource 700 million tablets by FY2028 and strengthen Japan’s off-patent medicines supply through a broader networked manufacturing strategy.
Generics Bulletin - April 24, 2026
Towa has agreed a manufacturing pact with Sanwa Kagaku Kenkyusho to add backup production capacity, outsource 700 million tablets by FY2028 and strengthen Japan’s off-patent medicines supply through a broader networked manufacturing strategy.
Generics Bulletin - April 24, 2026
CEO: Bayer Leaner And Faster But Not Out Of The Woods
Bill Anderson has told stockholders that two years into a major restructuring plan, the German company was "leaner and faster" than before but there were still "big milestones and decisions ahead."
Scrip - April 24, 2026
Bill Anderson has told stockholders that two years into a major restructuring plan, the German company was "leaner and faster" than before but there were still "big milestones and decisions ahead."
Scrip - April 24, 2026
Ipsen Bets On Pipeline Catalysts And Rare Disease Momentum To Power 2026 Growth
After posting a decent set of financials, Ipsen is banking on upcoming pipeline catalysts and portfolio diversification to sustain growth beyond its legacy franchise.
Scrip - April 24, 2026
After posting a decent set of financials, Ipsen is banking on upcoming pipeline catalysts and portfolio diversification to sustain growth beyond its legacy franchise.
Scrip - April 24, 2026
Astellas Settles Another Mirabegron Lawsuit, With MSN Pharma
The agreement follows a series of earlier legal settlements over generic versions of overactive bladder drug Myrbetriq in the US market.
Scrip - April 24, 2026
The agreement follows a series of earlier legal settlements over generic versions of overactive bladder drug Myrbetriq in the US market.
Scrip - April 24, 2026
Thermo Fisher Raises Guidance As Q1 Results Dodge Tariff Concerns
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026
US FDA Looks Beyond Monoclonal Antibodies To Encourage Animal Testing Alternatives
Weight-of-evidence approaches and reduced duration testing will be extended to other biological molecules, new chemical entities, and medical countermeasures, agency says in a report evaluating its progress on new approach methods.
HBW Insight - April 24, 2026
Weight-of-evidence approaches and reduced duration testing will be extended to other biological molecules, new chemical entities, and medical countermeasures, agency says in a report evaluating its progress on new approach methods.
HBW Insight - April 24, 2026
US Consumer Health News Digest: Business, Regulation, Science
HBW Insight notes significant recent news from across the US consumer health industry and marketplace in this first installment of a weekly digest.
HBW Insight - April 24, 2026
HBW Insight notes significant recent news from across the US consumer health industry and marketplace in this first installment of a weekly digest.
HBW Insight - April 24, 2026
Double Billing: Regeneron MFN Deal Announced Along With Approval Of Its Gene Therapy
Treatment for deafness is the first gene therapy approved under the FDA Commissioner’s National Priority Voucher program.
Scrip - April 24, 2026
Treatment for deafness is the first gene therapy approved under the FDA Commissioner’s National Priority Voucher program.
Scrip - April 24, 2026
Pipeline Watch: Twelve Approvals And Nine Phase III Readouts
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 24, 2026
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Scrip - April 24, 2026
Hansa’s Europe Miss For Lead Drug Raises US Launch Stakes
Hansa’s launch preparations are underway ahead of an expected US FDA decision on imlifidase, its desensitization therapy for kidney transplant patients, later this year.
Scrip - April 24, 2026
Hansa’s launch preparations are underway ahead of an expected US FDA decision on imlifidase, its desensitization therapy for kidney transplant patients, later this year.
Scrip - April 24, 2026
CEO: Bayer Leaner And Faster But Not Out Of The Woods
Bill Anderson has told stockholders that two years into a major restructuring plan, the German company was "leaner and faster" than before but there were still "big milestones and decisions ahead."
Scrip - April 24, 2026
Bill Anderson has told stockholders that two years into a major restructuring plan, the German company was "leaner and faster" than before but there were still "big milestones and decisions ahead."
Scrip - April 24, 2026
Ipsen Bets On Pipeline Catalysts And Rare Disease Momentum To Power 2026 Growth
After posting a decent set of financials, Ipsen is banking on upcoming pipeline catalysts and portfolio diversification to sustain growth beyond its legacy franchise.
Scrip - April 24, 2026
After posting a decent set of financials, Ipsen is banking on upcoming pipeline catalysts and portfolio diversification to sustain growth beyond its legacy franchise.
Scrip - April 24, 2026
Astellas Settles Another Mirabegron Lawsuit, With MSN Pharma
The agreement follows a series of earlier legal settlements over generic versions of overactive bladder drug Myrbetriq in the US market.
Scrip - April 24, 2026
The agreement follows a series of earlier legal settlements over generic versions of overactive bladder drug Myrbetriq in the US market.
Scrip - April 24, 2026
Double Billing: Regeneron MFN Deal Announced Along With Approval Of Its Gene Therapy
Treatment for deafness is the first gene therapy approved under the FDA Commissioner’s National Priority Voucher program.
Scrip - April 24, 2026
Treatment for deafness is the first gene therapy approved under the FDA Commissioner’s National Priority Voucher program.
Scrip - April 24, 2026
FDA Issues Early Alert On Medline Syringes
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026
The FDA flagged Medline's angiographic syringes as potentially posing a high risk to patients after a rotating adapter component was found to unwind during use, which could cause biohazard exposure or air embolism.
Medtech Insight - April 24, 2026
EU Unlocks New Funding For Health AI Projects
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026
Seven calls for proposals totaling €63.2m offer a glimpse into the EU’s priorities for AI and digital health.
Medtech Insight - April 24, 2026
Thermo Fisher Raises Guidance As Q1 Results Dodge Tariff Concerns
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026
Company saw Q1 revenues grow by 6%, but shares slid as analysts questioned growth structure.
Medtech Insight - April 24, 2026
Interparfums Navigating ‘More Selective’ Consumers As Q1 Sales Rise
Fragrances specialist Interparfums highlighted the headwinds facing its business, and the wider industry, as it reported a rise in first-quarter sales.
HBW Insight - April 24, 2026
Fragrances specialist Interparfums highlighted the headwinds facing its business, and the wider industry, as it reported a rise in first-quarter sales.
HBW Insight - April 24, 2026
US FDA Looks Beyond Monoclonal Antibodies To Encourage Animal Testing Alternatives
Weight-of-evidence approaches and reduced duration testing will be extended to other biological molecules, new chemical entities, and medical countermeasures, agency says in a report evaluating its progress on new approach methods.
HBW Insight - April 24, 2026
Weight-of-evidence approaches and reduced duration testing will be extended to other biological molecules, new chemical entities, and medical countermeasures, agency says in a report evaluating its progress on new approach methods.
HBW Insight - April 24, 2026
US Consumer Health News Digest: Business, Regulation, Science
HBW Insight notes significant recent news from across the US consumer health industry and marketplace in this first installment of a weekly digest.
HBW Insight - April 24, 2026
HBW Insight notes significant recent news from across the US consumer health industry and marketplace in this first installment of a weekly digest.
HBW Insight - April 24, 2026
Biocon Secures Health Canada Approval For Two Denosumab Biosimilars
Following two more approvals from Health Canada, biosimilars Bosaya and Vevzuo are ready to compete for their market share of denosumab success.
Generics Bulletin - April 24, 2026
Following two more approvals from Health Canada, biosimilars Bosaya and Vevzuo are ready to compete for their market share of denosumab success.
Generics Bulletin - April 24, 2026
Europe Widens Competition Path For Generic Peptides
Europe’s top court has ruled that synthetic medicines may use the EU generic pathway even when the reference product is a biologic, provided Article 10 criteria are met, in a decision with potentially significant implications for peptide competition.
Generics Bulletin - April 24, 2026
Europe’s top court has ruled that synthetic medicines may use the EU generic pathway even when the reference product is a biologic, provided Article 10 criteria are met, in a decision with potentially significant implications for peptide competition.
Generics Bulletin - April 24, 2026
EU Nod Arrives For Viatris’s Ibrance Rival
As Viatris received a positive opinion from the EMA’s CHMP for its palbociclib generic, Intas also racked up an endorsement for the region's latest biosimilar rival to Lucentis.
Generics Bulletin - April 24, 2026
As Viatris received a positive opinion from the EMA’s CHMP for its palbociclib generic, Intas also racked up an endorsement for the region's latest biosimilar rival to Lucentis.
Generics Bulletin - April 24, 2026
Towa Builds Further Backup Network For Drug Shortages
Towa has agreed a manufacturing pact with Sanwa Kagaku Kenkyusho to add backup production capacity, outsource 700 million tablets by FY2028 and strengthen Japan’s off-patent medicines supply through a broader networked manufacturing strategy.
Generics Bulletin - April 24, 2026
Towa has agreed a manufacturing pact with Sanwa Kagaku Kenkyusho to add backup production capacity, outsource 700 million tablets by FY2028 and strengthen Japan’s off-patent medicines supply through a broader networked manufacturing strategy.
Generics Bulletin - April 24, 2026
Partial Inhibition, Full Ambition: Regeneron Bets Its Neurology Future On Cemdisiran
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026
With an FDA submission confirmed and a priority review voucher in play, Regeneron is targeting a year-end approval, but the competitive math in gMG is unforgiving.
In Vivo - April 22, 2026
Pharma’s Pipeline Size Dipped In 2025
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026
There has been a fall in the number of drugs in development, latest annual data from Citeline show, but the figure is thought to point to a flattening, rather than contracting, of the pipeline.
In Vivo - April 22, 2026
The 10-80-10 Investment Rule: Preparation Is All
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026
It's never an even playing field for healthtech founders seeking investor interest. A high-level BioWales 2026 panel offered advice to hopeful entrepreneurs.
In Vivo - April 22, 2026